Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2018, Cilt: 4 Sayı: 2, 1 - 6, 30.08.2018
https://doi.org/10.19127/mbsjohs.442649

Öz

Kaynakça

  • 1. Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S et al.. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry, 2006:59:673-80.
  • 2. Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. Eur Child Adolesc Psychiatry, 2000:9:147-61.
  • 3. Birmaher B, Brent D. Practice parameters for the assessment and treatment of children and adolescent with depressive disorder. J Am Acad Child Adolesc Psychiatry, 1998:37:63-83.
  • 4. Herken H. Depresyon etyolojisinde genetik kanıtlar. Klinik psikiyatri. 2002:4:5-10.
  • 5. Uzbay İT. Nöroplastisite ve Depresyon. 1. baskı. Ankara: Çizgi Tıp yayınevi, 2005.
  • 6. Tapia-Arancibia L, Rage F, Givalois L and Aracibia S. Physiology of BDNF: focus on hypothalamic function. Front in Neuroendocrinol, 2004:25:77-107.
  • 7. Aydemir Ö, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Progr Neuro-Psychopharmacol Biol Pschiatry, 2005:29:261-5.
  • 8. Kalueff AV, Wheaton M, Ren-Patterson R, Murphy DL. Brain-derived neurotrophic factor, serotonin transporter, and depression: comment on Kaufman et al. Biological psychiatry, 2007:61:1112-1113..
  • 9. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research Reviews, 2004:45:104-14.
  • 10. Katoh-Semba R, Wakako R, Komari T et al. Age-related changes in BDNF levels in human serum: differences between autism cases and normal control. Int J Dev Neuroscience, 2007:25:367-72.
  • 11. McCusker RH, McCrea K, Zunich S, Dantzer R, Broussard SR, Johnson RW et al..Insuline-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocorticalneurons. J Neuroimmunol, 2006:179:186-90.
  • 12. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol, 2007:18:391-418.
  • 13. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-1 and BDNF leads to long-lasting antidepressant-like effects. Brain Res, 2005:1037: 204-8.
  • 14. Öy B. Çocukluk Depresyonu Derecelendirme Ölçeği: Sağlıklı ve Çocuk Ruh Sağlığı Kliniğine Başvuran Çocuklarda Uygulanması. Türk Psikiyatri Dergisi, 1991:2:137-40.
  • 15. Öner N, Le Compte A (ed). Süreksiz durumluluk/ sürekli kaygı envanteri el kitabı. İkinci baskı. İstanbul: Boğaziçi Üniversitesi Yayınları, 1985:1-26.
  • 16. Aydemir Ö, Deveci A, Taskin OE, Taneli F, Esen-Danacı A. Serum Brain-derived neurotrophic factor level in dystimia: A comparative study with major depressive disorder. Prog Neuro-Psychopharmacol Biol Pschiatry, 2007:31:1023-26.
  • 17. Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF levels in depressive patients. J AffectDisord, 2007:101:239-44.
  • 18. Başterzi AD, Yazici K, Aslan E, Delialioğlu N, Taşdelen B, Acar ŞT et al.. Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry, 2009:33:281-285.
  • 19. Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E et al..Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J PsychiatrRes, 1999:33:121-7.
  • 20. Duman RS, Malberg J, Nakagawa S andD’Sa C. Neuronal plasticity and survival in mood disorders. BiolPsychiatry, 2000:48:732-39.
  • 21. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry, 2002:17:306-310.
  • 22. Wichers M, Kenis G, Jacobs N et al. The BDNF Val66MetX5-HTTLPRX Child adversity interaction and depressive symptoms: An attempt at replication. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 2008:147:120-123.
  • 23. Bhatia SK, Bhatia SC. Childhood and adolescent depression. American Family Physician, 2007:75:73-80.
  • 24. O’Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW. Regulationog IGF-I function by proinflammatory cytokines: At th einterface of immunology and endocrinology. Cellular Immunology, 2008:252:91-110.
  • 25. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-I, BDNF andserotonin. Ageing Rresearch Reviews, 2004:3:445-64.

Investigation of Serum Brain Derived Neurotrophic Factor Levels in Children and Adolescents Aged 12 to 18 Years with Depressive Disorder

Yıl 2018, Cilt: 4 Sayı: 2, 1 - 6, 30.08.2018
https://doi.org/10.19127/mbsjohs.442649

Öz

Objective: It has been suggested that the neuroplastic processis associated with the pathogenesis of psychiatric disorders including depressive disorder. It is thought that brain
derived neurotrophic factor (BDNF) is an important factor in neuroplasticity in depressive disorder.
BDNF is play an important role in survival of neurons,
synaptic plasticity, formation of synaptic connections and neurodevelopment. Insulin like growth factor-1 (IGF-1) is found in various areas of the brain.
IGF-1 is involved in brain growth, development and mylination, also in brain plasticity. IGF-1 affect the genesis of neurons, astrocytes, oligodendrocytes
and endothelial cells.
In this study we aimed to evaluate serum levels of BDNF and IGF-1, which is also accepted as a neurotrophic factor, in children and adolescents between
12-18 years with depressive disorder.



Methods: The patient group was composed of 35 subjects (26 females; 9 male), while the control group was composed of 22 subjects (14 females; 8 male). Sociodemographic form,
Kovac’s depression scale, and state-trait anxiety inventory were applied to all subjects. Serum BDNF and IGF-1 levels were measured with ELISA.
Moreover complete blood count,
biochemical tests, thyroid and sex hormones were tested.

Results: There was no significant difference between the patient group and the control group in terms of the BDNF and IGF-1 levels (respectively p values 0.547 and 0.968). When the groups divided into female
and male subgroups, statistically significant differences were not found again. Moreover age, gender, menstrual states, suicide attempts, suicide thoughts,
smoking and Body Mass Index had no effects on the BDNF. There was also no effects on IGF-1 levels, except age. There was negative correlation
between age and IGF-1 in all subjects.

Conclusion: The results of this study do not support the association of depressive disorder with changes in serum BDNF and IGF-1 levels in children and adolescents. But larger
prospective studies are needed to show better the effects of these factors.

Kaynakça

  • 1. Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S et al.. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry, 2006:59:673-80.
  • 2. Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. Eur Child Adolesc Psychiatry, 2000:9:147-61.
  • 3. Birmaher B, Brent D. Practice parameters for the assessment and treatment of children and adolescent with depressive disorder. J Am Acad Child Adolesc Psychiatry, 1998:37:63-83.
  • 4. Herken H. Depresyon etyolojisinde genetik kanıtlar. Klinik psikiyatri. 2002:4:5-10.
  • 5. Uzbay İT. Nöroplastisite ve Depresyon. 1. baskı. Ankara: Çizgi Tıp yayınevi, 2005.
  • 6. Tapia-Arancibia L, Rage F, Givalois L and Aracibia S. Physiology of BDNF: focus on hypothalamic function. Front in Neuroendocrinol, 2004:25:77-107.
  • 7. Aydemir Ö, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Progr Neuro-Psychopharmacol Biol Pschiatry, 2005:29:261-5.
  • 8. Kalueff AV, Wheaton M, Ren-Patterson R, Murphy DL. Brain-derived neurotrophic factor, serotonin transporter, and depression: comment on Kaufman et al. Biological psychiatry, 2007:61:1112-1113..
  • 9. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research Reviews, 2004:45:104-14.
  • 10. Katoh-Semba R, Wakako R, Komari T et al. Age-related changes in BDNF levels in human serum: differences between autism cases and normal control. Int J Dev Neuroscience, 2007:25:367-72.
  • 11. McCusker RH, McCrea K, Zunich S, Dantzer R, Broussard SR, Johnson RW et al..Insuline-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocorticalneurons. J Neuroimmunol, 2006:179:186-90.
  • 12. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol, 2007:18:391-418.
  • 13. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-1 and BDNF leads to long-lasting antidepressant-like effects. Brain Res, 2005:1037: 204-8.
  • 14. Öy B. Çocukluk Depresyonu Derecelendirme Ölçeği: Sağlıklı ve Çocuk Ruh Sağlığı Kliniğine Başvuran Çocuklarda Uygulanması. Türk Psikiyatri Dergisi, 1991:2:137-40.
  • 15. Öner N, Le Compte A (ed). Süreksiz durumluluk/ sürekli kaygı envanteri el kitabı. İkinci baskı. İstanbul: Boğaziçi Üniversitesi Yayınları, 1985:1-26.
  • 16. Aydemir Ö, Deveci A, Taskin OE, Taneli F, Esen-Danacı A. Serum Brain-derived neurotrophic factor level in dystimia: A comparative study with major depressive disorder. Prog Neuro-Psychopharmacol Biol Pschiatry, 2007:31:1023-26.
  • 17. Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF levels in depressive patients. J AffectDisord, 2007:101:239-44.
  • 18. Başterzi AD, Yazici K, Aslan E, Delialioğlu N, Taşdelen B, Acar ŞT et al.. Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry, 2009:33:281-285.
  • 19. Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E et al..Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J PsychiatrRes, 1999:33:121-7.
  • 20. Duman RS, Malberg J, Nakagawa S andD’Sa C. Neuronal plasticity and survival in mood disorders. BiolPsychiatry, 2000:48:732-39.
  • 21. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry, 2002:17:306-310.
  • 22. Wichers M, Kenis G, Jacobs N et al. The BDNF Val66MetX5-HTTLPRX Child adversity interaction and depressive symptoms: An attempt at replication. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 2008:147:120-123.
  • 23. Bhatia SK, Bhatia SC. Childhood and adolescent depression. American Family Physician, 2007:75:73-80.
  • 24. O’Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW. Regulationog IGF-I function by proinflammatory cytokines: At th einterface of immunology and endocrinology. Cellular Immunology, 2008:252:91-110.
  • 25. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-I, BDNF andserotonin. Ageing Rresearch Reviews, 2004:3:445-64.
Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Makaleleri
Yazarlar

Erman Esnafoglu

Yeşim Taneli

Emine Kırhan Bu kişi benim

Melehat Dirican Bu kişi benim

Yayımlanma Tarihi 30 Ağustos 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 4 Sayı: 2

Kaynak Göster

Vancouver Esnafoglu E, Taneli Y, Kırhan E, Dirican M. Investigation of Serum Brain Derived Neurotrophic Factor Levels in Children and Adolescents Aged 12 to 18 Years with Depressive Disorder. Middle Black Sea Journal of Health Science. 2018;4(2):1-6.

22104 22108 22107 22106 22105 22103 22109   22137  2210222110     e-ISSN 2149-7796